Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goggin

Showing results (651-660 of 669) with videos related to

Pageof 67
Sort By:
Alternation|October 14, 2014
The Translation and Cultural Adaptation of Patient-reported Outcome Measures for a Clinical Study Involving Traditional Health Providers and Bio-medically Trained PractitionersKathy Goggin, Nceba Gqaleni, Adonica Lindokuhle Mbhele, et al.
Cancer Research|September 17, 2016
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell CarcinomaEli M Wallace, James P Rizzi, Guangzhou Han, et al.
Journal of Medicinal Chemistry|October 6, 2018
Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)Paul M Wehn, James P Rizzi, Darryl D Dixon, et al.
ERJ Open Research|April 20, 2023
The Palestinian primary ciliary dyskinesia population: first results of the diagnostic and genetic spectrumNisreen Rumman, Mahmoud R Fassad, Corine Driessens, et al.
Thorax|September 1, 2018
Risk factors for situs defects and congenital heart disease in primary ciliary dyskinesiaSunayna Best, Amelia Shoemark, Bruna Rubbo, et al.
Journal of Medicinal Chemistry|January 5, 2001
Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclaseD L Selwood, D G Brummell, J Budworth, et al.
Neuropharmacology|October 5, 2014
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative modelsJulie A Kelly, Noreen T Boyle, Natalie Cole, et al.
Journal of Medicinal Chemistry|October 3, 2013
Benzazepinones and benzoxazepinones as antagonists of inhibitor of apoptosis proteins (IAPs) selective for the second baculovirus IAP repeat (BIR2) domainAndrew F Donnell, Christophe Michoud, Kenneth C Rupert, et al.
Journal of Medicinal Chemistry|October 8, 2013
Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domainRobert F Kester, Andrew F Donnell, Yan Lou, et al.
Journal of Medical Genetics|December 28, 2019
Clinical utility of NGS diagnosis and disease stratification in a multiethnic primary ciliary dyskinesia cohortMahmoud R Fassad, Mitali P Patel, Amelia Shoemark, et al.
Pageof 67

Showing results (651-660 of 669) with videos related to

Sort By:
Pageof 67
Alternation|October 14, 2014
The Translation and Cultural Adaptation of Patient-reported Outcome Measures for a Clinical Study Involving Traditional Health Providers and Bio-medically Trained PractitionersKathy Goggin, Nceba Gqaleni, Adonica Lindokuhle Mbhele, et al.
Cancer Research|September 17, 2016
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell CarcinomaEli M Wallace, James P Rizzi, Guangzhou Han, et al.
Journal of Medicinal Chemistry|October 6, 2018
Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)Paul M Wehn, James P Rizzi, Darryl D Dixon, et al.
ERJ Open Research|April 20, 2023
The Palestinian primary ciliary dyskinesia population: first results of the diagnostic and genetic spectrumNisreen Rumman, Mahmoud R Fassad, Corine Driessens, et al.
Thorax|September 1, 2018
Risk factors for situs defects and congenital heart disease in primary ciliary dyskinesiaSunayna Best, Amelia Shoemark, Bruna Rubbo, et al.
Journal of Medicinal Chemistry|January 5, 2001
Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclaseD L Selwood, D G Brummell, J Budworth, et al.
Neuropharmacology|October 5, 2014
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative modelsJulie A Kelly, Noreen T Boyle, Natalie Cole, et al.
Journal of Medicinal Chemistry|October 3, 2013
Benzazepinones and benzoxazepinones as antagonists of inhibitor of apoptosis proteins (IAPs) selective for the second baculovirus IAP repeat (BIR2) domainAndrew F Donnell, Christophe Michoud, Kenneth C Rupert, et al.
Journal of Medicinal Chemistry|October 8, 2013
Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domainRobert F Kester, Andrew F Donnell, Yan Lou, et al.
Journal of Medical Genetics|December 28, 2019
Clinical utility of NGS diagnosis and disease stratification in a multiethnic primary ciliary dyskinesia cohortMahmoud R Fassad, Mitali P Patel, Amelia Shoemark, et al.
Pageof 67